{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:13:50Z","timestamp":1781626430194,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jad.2023.01.024","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T02:30:01Z","timestamp":1672972201000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["When to stop medication in unipolar depression: A systematic review and a meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"325","author":[{"given":"Mehmet Kemal","family":"Ar\u0131kan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhan","family":"\u0130lhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Pogarell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131\u015f","family":"Metin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.01.024_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.jad.2023.01.024_bb0010","series-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015","first-page":"76","volume":"16","author":"Bauer","year":"2015"},{"key":"10.1016\/j.jad.2023.01.024_bb0015","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/0269881112441866","article-title":"A randomized clinical study of lu AA21004 in the prevention of relapse in patients with major depressive disorder","volume":"26","author":"Boulenger","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2023.01.024_bb0025","first-page":"16","article-title":"Real-world data on SSRI antidepressant side effects","volume":"6","author":"Cascade","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jad.2023.01.024_bb0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1017\/S003329171100239X","article-title":"Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D","volume":"42","author":"Clark","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2023.01.024_bb0035","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/14737175.2020.1804870","article-title":"Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations","volume":"20","author":"Cosci","year":"2020","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jad.2023.01.024_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/hup.269","article-title":"Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression*","volume":"16","author":"Dalery","year":"2001","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jad.2023.01.024_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.107143","article-title":"The costs incurred by the NHS in England due to the unnecessary prescribing of dependency-forming medications","volume":"125","author":"Davies","year":"2022","journal-title":"Addict. Behav."},{"key":"10.1016\/j.jad.2023.01.024_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1192\/bjp.160.2.217","article-title":"Sertraline in the prevention of depression","volume":"160","author":"Doogan","year":"1992","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/da.22872","article-title":"Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"36","author":"Durgam","year":"2019","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jad.2023.01.024_bb0060","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/YIC.0000000000000236","article-title":"Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Durgam","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0000000000000570","article-title":"Behavioral toxicity revisited","volume":"36","author":"Fava","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0070","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jpsychires.2005.06.005","article-title":"Management of depression relapse: re-initiation of duloxetine treatment or dose increase","volume":"40","author":"Fava","year":"2006","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.01.024_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199901000-00002","article-title":"Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression","volume":"14","author":"Feiger","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2023.01.024_bb9000","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/wps.20906","article-title":"Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis","volume":"20","author":"Furukawa","year":"2021","journal-title":"World Psychiatry : Off. J. World Psychiatric Association (WPA)"},{"key":"10.1016\/j.jad.2023.01.024_bb0080","series-title":"Practice Guideline for the Treatment of Patients With Major Depressive Disorder Third Edition Work Group on Major Depressive Disorder","author":"Gelenberg","year":"2010"},{"key":"10.1016\/j.jad.2023.01.024_bb0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004714-200108000-00009","article-title":"Fluoxetine in the prevention of depressive recurrences: a double-blind study","volume":"21","author":"Gilaberte","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0090","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.08m04548","article-title":"Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial","volume":"70","author":"Goodwin","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.JGP.0000240823.94522.4c","article-title":"Escitalopram prevents relapse in older patients with major depressive disorder","volume":"15","author":"Gorwood","year":"2007","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2020.3650","article-title":"Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder","volume":"78","author":"Guidi","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320921694","article-title":"How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding","volume":"10","author":"Hengartner","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1192\/bjp.178.4.304","article-title":"Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy","volume":"178","author":"Hochstrasser","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000480456","article-title":"Long-term and short-term antidepressant use in general practice: data from a large cohort in the Netherlands","volume":"86","author":"Huijbregts","year":"2017","journal-title":"Psychother. Psychosom."},{"issue":"1","key":"10.1016\/j.jad.2023.01.024_bb6000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.yic.0000182118.57510.d1","article-title":"A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan","volume":"21","author":"Kamijima","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41380-020-0843-0","article-title":"Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis","volume":"26","author":"Kato","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0130","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/jama.280.19.1665","article-title":"Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial","volume":"280","author":"Keller","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2023.01.024_bb0135","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1192\/bjp.181.1.29","article-title":"Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy","volume":"181","author":"Klysner","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0145","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.4088\/JCP.v67n1115","article-title":"Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial","volume":"67","author":"Kornstein","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/YIC.0b013e328314e2cb","article-title":"Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75\u2013225 mg\/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study","volume":"23","author":"Kornstein","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0155","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1176\/appi.ajp.161.5.836","article-title":"A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder","volume":"161","author":"L\u00e9pine","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jad.2021.04.045","article-title":"Discontinuation of antidepressants: is there a minimum time on treatment that will reduce relapse risk?","volume":"290","author":"Liu","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.01.024_bb0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archpsyc.63.5.521","article-title":"Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Lustman","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0004867420979353","article-title":"The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders","volume":"55","author":"Malhi","year":"2021","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/JGP.0b013e3181f1803d","article-title":"Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs","volume":"19","author":"Mark","year":"2011","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00127-016-1306-4","article-title":"Influences on antidepressant prescribing trends in the UK: 1995\u20132011","volume":"52","author":"Mars","year":"2017","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.jad.2023.01.024_bb0185","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1176\/ajp.2006.163.9.1542","article-title":"Predictors of relapse in a prospective study of fluoxetine treatment of major depression","volume":"163","author":"McGrath","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2023.01.024_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00228-004-0726-3","article-title":"Incidence and determinants of long-term use of antidepressants","volume":"60","author":"Meijer","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00004850-199300830-00009","article-title":"Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression","volume":"8","author":"Montgomery","year":"1993","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0200","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4088\/JCP.v65n0307","article-title":"Venlafaxine versus placebo in the preventive treatment of recurrent major depression","volume":"65","author":"Montgomery","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004850-199300830-00008","article-title":"A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression","volume":"8","author":"Montgomery","year":"1993","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0210","article-title":"Depression: the nice guideline on the treatment and management of depression in adults","volume":"705","year":"2010","journal-title":"Economist"},{"key":"10.1016\/j.jad.2023.01.024_bb0215","series-title":"Health at a Glance 2021","author":"OECD","year":"2021"},{"key":"10.1016\/j.jad.2023.01.024_bb0220","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jama.2018.1150","article-title":"Health care spending in the United States and other high-income countries","volume":"319","author":"Papanicolas","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2023.01.024_bb0225","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.08m04756","article-title":"Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Perahia","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0230","series-title":"APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts Guideline Development Panel for the Treatment of Depressive Disorders Approved by APA Council of REPRESENTATIVES","year":"2019"},{"key":"10.1016\/j.jad.2023.01.024_bb0235","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4088\/JCP.v65n0107","article-title":"Escitalopram continuation treatment prevents relapse of depressive episodes","volume":"65","author":"Rapaport","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0240","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1176\/ajp.155.9.1247","article-title":"Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment","volume":"155","author":"Reimherr","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0245","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JCP.0b013e3181c94c4d","article-title":"Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial","volume":"30","author":"Rickels","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004850-199503001-00006","article-title":"Citalopram in doses of 20\u201360 mg is effective in depression relapse prevention: a placebo-controlled 6 month study","volume":"10","author":"Robert","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0255","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4088\/JCP.12m07974","article-title":"Efficacy and safety of desvenlafaxine 50 mg\/d for prevention of relapse in major depressive disorder:a randomized controlled trial","volume":"74","author":"Rosenthal","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004850-200015030-00002","article-title":"Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group","volume":"15","author":"Rouillon","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jad.2023.01.024_bb0265","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4088\/JCP.v61n1107","article-title":"The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder","volume":"61","author":"Schmidt","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0270","first-page":"10","article-title":"A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40\u2013120mg\/day for prevention of relapse in patients with major depressive disorder","volume":"11","author":"Shiovitz","year":"2014","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.01.024_bb0275","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.2019.13978","article-title":"Waste in the US health care system: estimated costs and potential for savings","volume":"322","author":"Shrank","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2023.01.024_bb0280","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpsychires.2003.10.004","article-title":"Extended-release venlafaxine in relapse prevention for patients with major depressive disorder","volume":"38","author":"Simon","year":"2004","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.01.024_bb0285","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00004850-199803000-00001","article-title":"Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study","volume":"13","author":"Terra","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.024_bb0290","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4088\/JCP.v62n1006","article-title":"Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients","volume":"62","author":"Thase","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0295","series-title":"VA\/DoD Clinical Practice Guideline for The Management of Major Depressive Disorder","year":"2016"},{"key":"10.1016\/j.jad.2023.01.024_bb0300","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4088\/JCP.v60n0610","article-title":"Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder","volume":"60","author":"Versiani","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2017.11.056","article-title":"Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis","volume":"228","author":"Wagner","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.01.024_bb0310","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4068\/cmj.2018.54.2.101","article-title":"Addressing the side effects of contemporary antidepressant drugs: a comprehensive review","volume":"54","author":"Wang","year":"2018","journal-title":"Chonnam. Med. J."},{"key":"10.1016\/j.jad.2023.01.024_bb0315","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0006-3223(01)01317-8","article-title":"Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression","volume":"51","author":"Weihs","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.024_bb0320","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1192\/bjp.182.6.492","article-title":"Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study","volume":"182","author":"Wilson","year":"2003","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:32:51Z","timestamp":1759030371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":66,"alternative-id":["S0165032723000320"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.01.024","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When to stop medication in unipolar depression: A systematic review and a meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}